Pub Date : 2022-01-01DOI: 10.54037/wjps.2021.91210
C. Parthiban, Aneesa, M. Sudhakar
A simple, specific and accurate reverse phase high performance liquid chromatographic method was developed for the simultaneous determination Sitagliptinand Etruglifloxinin pharmaceutical dosage form. The column used was Discovery C18(250mm x 4.6 mm, 5m)in isocratic mode, with mobile phase containing phosphatebufferandacetonitrile (45:55v/v). The buffer is prepared by adding accurately weighed 1.36gm of PotassiumdihyrogenOrtho phosphate in a 1000ml of Volumetric flask add about 900ml of milli-Q water added and degas to sonicate and finally make up the volume with water then pH adjusted to 5.4with dil. Orthophosphoric acid solution.The flow rate was 1.0ml/ min and effluents were monitored at 260nm. The retention times of Sitagliptinand Etruglifloxinwere found to be 2.381min and 3.429min, respectively. The linearity for Sitagliptinand Etruglifloxinwere in the range of 25-150μg/mland 3.75-22.5μg/ml respectively. The recoveries of Sitagliptinand Etruglifloxinwere found to be 99.46to 101.19% and 99.36to 100.99%, respectively. The proposed method was validated and successfully applied to the estimation of Sitagliptinand Etruglifloxinin combined tablet dosage forms.
建立了一种简便、特异、准确的反相高效液相色谱法同时测定西格列汀和依格列星宁制剂剂型的方法。色谱柱为Discovery C18(250mm x 4.6 mm, 5m)，等压柱，流动相为磷酸缓冲液和乙腈(45:55v/v)。缓冲液的制备方法为:在1000ml的容量瓶中加入精确称量的1.36gm磷酸二氢钾，加入约900ml的ml - q水，然后脱气进行超声波处理，最后用水补齐体积，用dil调节pH至5.4。正磷酸溶液。流速1.0ml/ min，在260nm处监测流出物。西格列汀和依trugliloxin保留时间分别为2.381min和3.429min。西格列汀和依曲列酮的线性范围分别为25 ~ 150μg/ml和3.75 ~ 22.5μg/ml。西格列汀和依曲列酮的加样回收率分别为99.46 ~ 101.19%和99.36 ~ 100.99%。该方法经验证并成功应用于西格列汀和依曲列呋辛联用片剂剂型的评价。
{"title":"Analytical method development and validation for simultaneous estimation of sitagliptin and etruglifloxin in bulk and pharmaceutical dosage form by RP-HPLC","authors":"C. Parthiban, Aneesa, M. Sudhakar","doi":"10.54037/wjps.2021.91210","DOIUrl":"https://doi.org/10.54037/wjps.2021.91210","url":null,"abstract":"A simple, specific and accurate reverse phase high performance liquid chromatographic method was developed for the simultaneous determination Sitagliptinand Etruglifloxinin pharmaceutical dosage form. The column used was Discovery C18(250mm x 4.6 mm, 5m)in isocratic mode, with mobile phase containing phosphatebufferandacetonitrile (45:55v/v). The buffer is prepared by adding accurately weighed 1.36gm of PotassiumdihyrogenOrtho phosphate in a 1000ml of Volumetric flask add about 900ml of milli-Q water added and degas to sonicate and finally make up the volume with water then pH adjusted to 5.4with dil. Orthophosphoric acid solution.The flow rate was 1.0ml/ min and effluents were monitored at 260nm. The retention times of Sitagliptinand Etruglifloxinwere found to be 2.381min and 3.429min, respectively. The linearity for Sitagliptinand Etruglifloxinwere in the range of 25-150μg/mland 3.75-22.5μg/ml respectively. The recoveries of Sitagliptinand Etruglifloxinwere found to be 99.46to 101.19% and 99.36to 100.99%, respectively. The proposed method was validated and successfully applied to the estimation of Sitagliptinand Etruglifloxinin combined tablet dosage forms.","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80567380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.54037/wjps.2022.100112
Harshini Gandla, M. Ajitha
A simple, Accurate, precise method was developed for the simultaneous estimation of the Netupitant and Palonosetron in Pharmaceutical dosage form. Chromatogram was run through Phenomenex C18 150 mm (4.6 x 150mm, 5μm) Mobile phase containing Buffer 60% 0.01N KH2PO4: 40% Acetonitrile was pumped through column at a flow rate of 1 ml/min. Temperature was maintained at 30°C. Optimized wavelength selected was 230.0 nm. Retention time of Palonosetron and Netupitant were found to be 2.266 min and 2.945 min. %RSD of the Netupitant and Palonosetron were and found to be 0.8 and 0.8 respectively. %Recovery was obtained as 101.08% and 100.35%for Netupitant and Palonosetron respectively. LOD, LOQ values obtained from regression equations of Netupitant and Palonosetron were 1.27, 3.86 and 0.002, 0.006. respectively. Regression equation of Netupitant is y =18431x + 50471.and y = 13091x + 11.98. of Palonosetron. Retention times were decreased and that run time was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.
{"title":"Stability Indicating Method Development and Validation for Simultaneous Estimation of the Netupitant and Palonosetron in Bulk and Pharmaceutical Dosage Form by RP-HPLC","authors":"Harshini Gandla, M. Ajitha","doi":"10.54037/wjps.2022.100112","DOIUrl":"https://doi.org/10.54037/wjps.2022.100112","url":null,"abstract":"A simple, Accurate, precise method was developed for the simultaneous estimation of the Netupitant and Palonosetron in Pharmaceutical dosage form. Chromatogram was run through Phenomenex C18 150 mm (4.6 x 150mm, 5μm) Mobile phase containing Buffer 60% 0.01N KH2PO4: 40% Acetonitrile was pumped through column at a flow rate of 1 ml/min. Temperature was maintained at 30°C. Optimized wavelength selected was 230.0 nm. Retention time of Palonosetron and Netupitant were found to be 2.266 min and 2.945 min. %RSD of the Netupitant and Palonosetron were and found to be 0.8 and 0.8 respectively. %Recovery was obtained as 101.08% and 100.35%for Netupitant and Palonosetron respectively. LOD, LOQ values obtained from regression equations of Netupitant and Palonosetron were 1.27, 3.86 and 0.002, 0.006. respectively. Regression equation of Netupitant is y =18431x + 50471.and y = 13091x + 11.98. of Palonosetron. Retention times were decreased and that run time was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91337348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.54037/wjps.2022.100111
P. Sharanya, S. Rani
A simple, Accurate, Precise method was developed for the simultaneous estimation of the Netarsudil and Latanoprost in opthalmic solution dosage form. Chromatogram was run through Zodiacsil C18 150 x 4.6 mm, 5μ. Mobile phase containing 0.01N Ammonium acetate: Methanol taken with in the ratio 55:45 was pumped through column on a flow rate at 1.0ml/min. Buffer used in this method was Ammonium acetate. Temperature was maintained at 30C. Optimized wavelength selected was 225nm. Retention time of Netarsudil and Latanoprost were found to be 2.222 min and 2.706 min. %RSD of the Netarsudil and Latanoprost were and found to be 0.5 and 0.8 respectively. %Recovery was obtained as 100.09% and 100.5% for Netarsudil and Latanoprost respectively. LOD, LOQ values obtained from regression equations of Netarsudil and Latanoprost were 0.07, 0.22 and 0.03, 0.09 respectively. Regression equation of Netarsudil y = 33253x +578.8 and y =45497x + 399.2 of Latanoprost. Retention times were decreased and that runtime was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.
{"title":"Development and Validation of Stability Indicating Analytical Method for the Simultaneous Estimation of Netarsudil and Latanoprost by RP-HPLC","authors":"P. Sharanya, S. Rani","doi":"10.54037/wjps.2022.100111","DOIUrl":"https://doi.org/10.54037/wjps.2022.100111","url":null,"abstract":"A simple, Accurate, Precise method was developed for the simultaneous estimation of the Netarsudil and Latanoprost in opthalmic solution dosage form. Chromatogram was run through Zodiacsil C18 150 x 4.6 mm, 5μ. Mobile phase containing 0.01N Ammonium acetate: Methanol taken with in the ratio 55:45 was pumped through column on a flow rate at 1.0ml/min. Buffer used in this method was Ammonium acetate. Temperature was maintained at 30C. Optimized wavelength selected was 225nm. Retention time of Netarsudil and Latanoprost were found to be 2.222 min and 2.706 min. %RSD of the Netarsudil and Latanoprost were and found to be 0.5 and 0.8 respectively. %Recovery was obtained as 100.09% and 100.5% for Netarsudil and Latanoprost respectively. LOD, LOQ values obtained from regression equations of Netarsudil and Latanoprost were 0.07, 0.22 and 0.03, 0.09 respectively. Regression equation of Netarsudil y = 33253x +578.8 and y =45497x + 399.2 of Latanoprost. Retention times were decreased and that runtime was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"111 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73957991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.54037/wjps.2022.100301
L. S.
Sauropus androgynus (L.) Merr., known traditionally as a multivitamin plant being cultivated in kitchen garden throughout south Indian region. Different organic solvents such as Ethyl acetate, hexane, and methanol were used to extract the bioactive compounds from the fresh air dried plant leaves. Among which ethyl acetate extracted most of the bioactive compounds efficiently. The compounds like tannins, flavonoids, proteins, terpenoids, coumarins and steroids were extracted at varied concentration remain parallel with their bioactive principles. Test organisms used were Escherichia coli, Staphylococcus aureus and Bacillus subtilis showed their sensitiveness with the ethyl acetate extract in vitro. The percentage scavenging activity was also observed to be more with ethyl acetate extract, which was found to increase with concentration.
{"title":"Variation in the efficacy of organic extrants for the phytochemical validation of Sauropus androgynus –a multivitamin plant","authors":"L. S.","doi":"10.54037/wjps.2022.100301","DOIUrl":"https://doi.org/10.54037/wjps.2022.100301","url":null,"abstract":"Sauropus androgynus (L.) Merr., known traditionally as a multivitamin plant being cultivated in kitchen garden throughout south Indian region. Different organic solvents such as Ethyl acetate, hexane, and methanol were used to extract the bioactive compounds from the fresh air dried plant leaves. Among which ethyl acetate extracted most of the bioactive compounds efficiently. The compounds like tannins, flavonoids, proteins, terpenoids, coumarins and steroids were extracted at varied concentration remain parallel with their bioactive principles. Test organisms used were Escherichia coli, Staphylococcus aureus and Bacillus subtilis showed their sensitiveness with the ethyl acetate extract in vitro. The percentage scavenging activity was also observed to be more with ethyl acetate extract, which was found to increase with concentration.","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86965475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aselin Puthenpurail, Hinal Rathi, Surya M Nauli, Ahmmed Ally
Monoclonal antibodies (mAbs) are increasingly being prescribed to patients and investigated in the field of medicine and research. This class of medication is unique due to its ability to be engineered into targeting a specific receptor. Numerous studies and reviews have reported the efficacy, potency, and clinical usage of mAbs in the treatment of a variety of diseases ranging from autoimmune disorders to malignant cancers. However, very few publications classify and provide a brief synopsis of mAbs that includes their pharmacological profiles. mechanisms of action, uses, and side effects in a concise manner. Therefore, this review aims to classify the current mAbs drugs used in clinical practice according to system diseases by providing a brief summary for each of them. For example, regarding cardiovascular disorders, mAbs such as Abciximab, Bevacizumab, and Digoxin Immune Fab will be reviewed. Denosumab, used to treat musculoskeletal disorders, will be also discussed. In addition, mAbs such as Adalimumab, Eculizumab, Natalizumab used in autoimmune disorders and Alemtuzumab, Trastuzumab, Cetuximab, and Rituximab that are prescribed for tumors will be reviewed. Finally, we shall discuss two mAbs that are IL-6 antagonists, Tocilizumab and Siltuximab, which are in ongoing clinical trials as potential treatments of COVID-19. The mAbs have profound benefits against chronic and malignant conditions, and the overall purpose of this review is to illustrate the basic pharmacological profiles of mAbs that physicians may find useful in establishing their management protocols.
{"title":"A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES.","authors":"Aselin Puthenpurail, Hinal Rathi, Surya M Nauli, Ahmmed Ally","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Monoclonal antibodies (mAbs) are increasingly being prescribed to patients and investigated in the field of medicine and research. This class of medication is unique due to its ability to be engineered into targeting a specific receptor. Numerous studies and reviews have reported the efficacy, potency, and clinical usage of mAbs in the treatment of a variety of diseases ranging from autoimmune disorders to malignant cancers. However, very few publications classify and provide a brief synopsis of mAbs that includes their pharmacological profiles. mechanisms of action, uses, and side effects in a concise manner. Therefore, this review aims to classify the current mAbs drugs used in clinical practice according to system diseases by providing a brief summary for each of them. For example, regarding cardiovascular disorders, mAbs such as Abciximab, Bevacizumab, and Digoxin Immune Fab will be reviewed. Denosumab, used to treat musculoskeletal disorders, will be also discussed. In addition, mAbs such as Adalimumab, Eculizumab, Natalizumab used in autoimmune disorders and Alemtuzumab, Trastuzumab, Cetuximab, and Rituximab that are prescribed for tumors will be reviewed. Finally, we shall discuss two mAbs that are IL-6 antagonists, Tocilizumab and Siltuximab, which are in ongoing clinical trials as potential treatments of COVID-19. The mAbs have profound benefits against chronic and malignant conditions, and the overall purpose of this review is to illustrate the basic pharmacological profiles of mAbs that physicians may find useful in establishing their management protocols.</p>","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"10 11","pages":"14-22"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775886/pdf/nihms-1770850.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39962856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.54037/wjps.2021.91102
Aleti Rajareddy, A. Divya
{"title":"Stability Indicating RP -HPLC Method Development and validation for the simultaneous estimation of Ertugliflozin and Sitagliptin in Bulk and Pharmaceutical Dosage form","authors":"Aleti Rajareddy, A. Divya","doi":"10.54037/wjps.2021.91102","DOIUrl":"https://doi.org/10.54037/wjps.2021.91102","url":null,"abstract":"","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81565773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.54037/wjps.2021.91005
Shubham A. Khadse, M. Mohite
{"title":"Formulation and evaluation of transdermal patch of stiripentol for treatment of seizures","authors":"Shubham A. Khadse, M. Mohite","doi":"10.54037/wjps.2021.91005","DOIUrl":"https://doi.org/10.54037/wjps.2021.91005","url":null,"abstract":"","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80582568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sachin Nivrutti Gadekar, Jeevan R. Rajguru, Dr. Subhash V. Deshmane, Dr. K. R. Biyani
{"title":"Review on solid dispersion for suitable drug","authors":"Sachin Nivrutti Gadekar, Jeevan R. Rajguru, Dr. Subhash V. Deshmane, Dr. K. R. Biyani","doi":"10.54037/wjps.2021.9911","DOIUrl":"https://doi.org/10.54037/wjps.2021.9911","url":null,"abstract":"","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79217987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gomathi Murugan, J. Chennakesavalu, Kalaiselvi Chinnamuthu, Soundharya Kaveri
{"title":"Formulation and evaluation of Mefenamic acid solid dispersions","authors":"Gomathi Murugan, J. Chennakesavalu, Kalaiselvi Chinnamuthu, Soundharya Kaveri","doi":"10.54037/wjps.2021.9902","DOIUrl":"https://doi.org/10.54037/wjps.2021.9902","url":null,"abstract":"","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"131 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77885565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.54037/wjps.2021.91107
Kushal Nandi, Rimum Ghosh, S. Mondal, D. Sen, D. Saha
{"title":"Source, isolation & impact of glycone and aglycone in human body","authors":"Kushal Nandi, Rimum Ghosh, S. Mondal, D. Sen, D. Saha","doi":"10.54037/wjps.2021.91107","DOIUrl":"https://doi.org/10.54037/wjps.2021.91107","url":null,"abstract":"","PeriodicalId":23975,"journal":{"name":"World journal of Pharmacy and pharmaceutical sciences","volume":"238 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75765274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：